bioMerieux (OTCMKTS:BMXMF) Reaches New 12-Month Low – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s stock price reached a new 52-week low on Thursday . The stock traded as low as $77.00 and last traded at $78.00, with a volume of 1105 shares. The stock had previously closed at $78.16.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BMXMF shares. Zacks Research upgraded bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a research note on Wednesday. Finally, Piper Sandler started coverage on bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

bioMerieux Stock Down 0.2%

The business has a 50-day moving average price of $89.39 and a two-hundred day moving average price of $108.45. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.